Kimer Med
Founded in 2020, Kimer Med is a New Zealand-based biotechnology company dedicated to ending the suffering caused by viral diseases through the development of safe and effective broad-spectrum antiviral therapeutics. Leveraging their proprietary platform for rapid antiviral drug design, Kimer Med targets the significant unmet need for treatments against the vast majority of human-infecting viruses, where 95% currently lack approved therapies. The company’s lead compound has demonstrated efficacy against all four serotypes of Dengue, as well as Zika virus, and is being advanced toward clinical trials. Kimer Med’s mission is to revolutionize antiviral treatment and enhance global health security by providing antiviral solutions for pandemic preparedness, and to address multiple neglected and currently untreatable viral diseases.
Kimer Med
56 Waimea Road Nelson South, Nelson 7010 New Zealand
What We Do
Kimer Med is advancing a pipeline of novel broad-spectrum antivirals. Multiple in vitro studies confirm our broad-spectrum capability, with efficacy against 21 different viruses across 9 virus families to date. These results include all four serotypes of Dengue, Zika, Influenza A, Rhinovirus, Coronavirus 229E, among others. Our compounds are being developed for use in pandemic preparedness, neglected tropical diseases, and as a medical countermeasure for healthcare and defense applications.
We have developed a proprietary platform enabling the rapid design and optimization of broad-spectrum antiviral drug candidates. Our platform approach accelerates drug discovery time, reducing cost. We employ a modular, iterative approach to optimise drug candidate efficacy, with the ability to design to circumvent specific viral defence mechanisms. The goal is a family of broad-spectrum antiviral therapeutics to meet high levels of unmet medical need.
Application Area
Infectious Diseases
Services
Biologics
Drugs
Key People
Rick Kiessig
Co-Founder & CEO, Chief Science Officer (CSO)
Dr Sophie Walker
Lead Scientist
Dr Lauren Nicol
Biomedical Scientist
Dr Geena McKenzie-Goldsmith
Biomedical Scientist
Dr Mauro Teixeira
Advisor
News & Updates
Named as an honoree in Fierce Biotech's 2024 'Fierce 15', recognizing the world's best and brightest in biotech.
Explores the complexities of Dengue fever, the challenges of developing treatments and vaccines for its four serotypes, and how Kimer Med’s approach targets a common viral process to overcome these barriers.
Highlights the importance of broad-spectrum antivirals for pandemic preparedness and Kimer Med’s alignment with global health priorities.
Announces a contract with Battelle Memorial Institute, funded by the US Defense Threat Reduction Agency, to develop antivirals for alphaviruses.
Highlights the global impact of flaviviruses and Kimer Med’s progress in developing antivirals for Dengue and Zika.
Emphasizes the importance of antiviral development for future pandemic response and Kimer Med’s commitment to this goal.